Ποια είναι η κεφαλαιοποίηση αγοράς για Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (2315)

Η κεφαλαιοποίηση αγοράς για Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (2315) είναι $3.22B

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (2315) Τιμή και Κεφαλαιοποίηση Αγοράς

Q: Ποια είναι η τιμή για Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (2315)

Η τιμή για Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (2315) είναι $7.93

Biocytogen Pharmaceuticals (Beijing) Co., Ltd., established in 2009 with its main office in Beijing, China, operates as a global biotechnology firm. Its core business involves the international research and development of antibody-based treatments. The company's drug development portfolio currently features a dozen key product candidates; specifically, two are actively progressing through multi-regional Phase II clinical trials, while another pair is in Phase I clinical assessments. Their therapeutic focus spans critical health areas such as oncology, autoimmune disorders, inflammatory conditions, metabolic diseases, and other ailments. Supporting these pharmaceutical ventures, the broader Beijing Biocytogen Co., Ltd. group, which commenced operations in 2008, also in Beijing, specializes in the creation and large-scale distribution of genetically modified animal models. This group provides comprehensive preclinical research services, leveraging its expertise in advanced gene-humanized models, patient-derived xenograft (PDX) models, and human immune system reconstituted models. Their extensive catalog includes a diverse array of specialized gene-edited mice and rats – for example, B-NDG mice, various Cre and knockout (KO) lines (like B-p53 KO and B-ApoE KO), knock-in (KI) models, B-hFcgrt (FcRn) mice, in addition to genome-edited human embryonic stem cells (hESC) and luciferase-reporter stable tumor cell lines. Furthermore, this overarching Biocytogen entity has cultivated an advanced platform dedicated to antibody discovery and development. It offers specialized pharmacology services across vital domains including tumor immunology, general oncology, autoimmune research, and both in vivo and in vitro pharmacological evaluations. The group also makes its products accessible through online sales channels. Beyond its primary location in Beijing, China, the company maintains additional facilities in Haimen, Jiangsu, and Shanghai, China, as well alongside international branches in Heidelberg, Germany, and Boston, United States.

Η τιμή για 2315	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$12,546.06 $3.22B	NVDA	$5.088T	+158,081.62%
$11,414.77 $3.22B	AAPL	$4.629T	+143,818.28%
$10,153.48 $3.22B	GOOG	$4.118T	+127,915.85%
$9,090.99 $3.22B	MSFT	$3.687T	+114,519.82%
$6,903.58 $3.22B	AMZN	$2.800T	+86,940.87%

Η τιμή για 2315

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$12,546.06 $3.22B